Press & News

ViewReleaseInStandardHtml

Boule Diagnostics – Change in number of shares and votes

In accordance with the decision of Boule Diagnostics AB's (publ) ("Boule") Annual General Meeting on May 14, 2018, a division of Boule’s shares has been implemented, whereby each existing share was divided into four (4) shares (so-called share split 4:1) with no change in Boule’s share capital.

After the division of shares, the total number of shares and votes in Boule has increased from 4,854,138 to 19,416,552. The quotient value has changed from SEK 1 per share to SEK 0.25 per share.

For further information, please contact:

Peter Ehrenheim, Chairman of the Board Boule Diagnostics AB, phone 0706-67 57 11
Fredrik Dalborg, CEO and Group President Boule Diagnostics AB, phone 070-558 51 05

About Boule Diagnostics AB (publ)

Boule Diagnostics AB is a global diagnostics company that develops, manufactures and markets instruments and consumable products for blood diagnostics. The company serves hospitals, clinics, laboratories and companies within blood diagnostics, in both human and veterinary hematology. The company operates via subsidiaries in Sweden, the USA and Mexico. The company’s products are sold globally primarily through distributors, supported by Boule’s own local sales and support personnel. The Boule shares are listed on Nasdaq Stockholm since 2011. www.boule.com 

The information was submitted for publication, through the agency of the contact person set out above, at 08.45 CET on June 29, 2018.